Delivery Order SPE2DB24D9144-SPE2DB25FCNAC
- Not listed
- The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order for XOLAIR 150 MG/ML syringes valued at $3,094.80. The contract, which was awarded on September 8, 2025, with an ultimate completion date of September 29, 2025, carries firm fixed-price terms and does not utilize a set-aside designation. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at approximately $142,000 by the Defense Logistics Agency (DLA) for XOLAIR 150 mg/ml syringes. The contract is firm fixed-price with an ultimate completion date of September 16, 2025, and was awarded on August 25, 2025, without set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery...
- The U.S. Defense Logistics Agency (DLA) awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a firm fixed-price delivery order valued at $8,561.10 for XOLAIR 150 mg/ml. This delivery order was issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, a $499.999 billion single-award vehicle valid through November 2026. The award carries no set-aside designation...
- The Defense Logistics Agency awarded a delivery order valued at $6,189.60 to DMS Pharmaceutical Group Inc. for XOLAIR 150 MG/ML syringes. This award, issued on September 10, 2025, with an ultimate completion date of October 1, 2025, represents a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, will fulfill this order. XOLAIR (omalizumab) is a biologic...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order valued at $3,094.80 by the Defense Logistics Agency on August 27, 2025, for the supply of Xolair 150 mg/ml syringes. The contract is structured as a firm fixed-price delivery order with an ultimate completion date of September 18, 2025, and carries no set-aside designation. This award is issued under DMS Pharmaceutical Group's larger single-award...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $11,605.50 to DMS Pharmaceutical Group Inc. for the supply of Xolair 150 mg/ml syringes. DMS Pharmaceutical Group is a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, and the contract carries no set-aside designation. The delivery order is scheduled for completion by September 24, 2025, and represents a single purchase under DMS Pharmaceutical Group's larger Indefinite Delivery...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $37,137.60 by the Defense Logistics Agency (DLA) on August 21, 2025. The delivery order, which carries no set-aside designation, is for Xolair 150 mg/ml syringes with an ultimate completion date of September 12, 2025. This award represents a single delivery order issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml syringes. The contract, valued at $22,325.76 with an ultimate completion date of September 16, 2025, was issued without a set-aside designation on August 25, 2025. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 150 mg/ml Xolair syringes. This $1,547.40 firm fixed-price delivery order was awarded on September 2, 2025, with an ultimate completion date of September 23, 2025. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on the open market despite its small business status. Xolair...
- The Defense Logistics Agency (DLA) awarded a delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of XOLAIR 300 mg/2 ml auto-injector units. The contract, valued at $10,273.38 with a firm fixed-price structure, was awarded on August 14, 2025, with an ultimate completion date of September 5, 2025. This delivery order was issued without a set-aside designation, and performance will take place at the...
- SPE2DB24D9144Indefinite Delivery Contract
- SPE2DB24D9144-SPE2DB25FCNACDelivery Order
The Defense Logistics Agency awarded DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, a delivery order valued at $1,547.40 for XOLAIR 75 mg/0.5 ml syringes. The award, issued on September 11, 2025, with an ultimate completion date of October 2, 2025, represents a firm fixed-price delivery order with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA's SPE2DB program, a $500 million single-award vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products for military health facilities worldwide. XOLAIR (omalizumab) is a monoclonal antibody therapeutic primarily used in the treatment of moderate-to-severe allergic asthma and chronic idiopathic urticaria. As a specialty biologic pharmaceutical, this product exemplifies the types of high-value, specialized medications that DMS Pharmaceutical Group supplies to Department of Defense healthcare facilities. The company's established role as a critical supplier in the federal pharmaceutical supply chain and its proven track record of delivering diverse pharmaceutical products—from oncology treatments to biologics and specialty injections—positions it as a preferred vendor for supporting military medical operations and healthcare needs.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.5k | 9/11/25 |